Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting

Antiviral Therapy

Volumn 16, Issue 6, 2011, Pages 815-824

  Reiberger, Thomas ^a   Obermeier, Martin ^b   Payer, Berit A ^a   Baumgarten, Axel ^c   Weitner, Lutwin ^d   Moll, Arend ^e   Christensen, Stefan ^f   Köppe, Siegfried ^g   Kundi, Michael ^h   Rieger, Armin ⁱ   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Medical Laboratory Berg   (Germany)

^c Praxis Dupke/Carganico/Baumgarten   (Germany)

^d Medical Center for Infectious Diseases   (Germany)

^e Praxiszentrum Kaiserdamm   (Germany)

^f Center for Interdisciplinary Medicine   (Germany)

^g Praxis Köppe Kreckel   (Germany)

^h Medical University of Vienna and Wiener Werkstaette for Suicide Research   (Austria)

ⁱ Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; COHORT ANALYSIS; DRUG CONTRAINDICATION; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ABUSE; LEUKOCYTE COUNT; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT REFUSAL; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80052959049     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1831     Document Type: Article

References (33)

1. Sherman KE, Rouster SD, Chung RT, Rajicic N, Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837. (Pubitemid 34194855)
2. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569. (Pubitemid 32709592)
3. + cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat 2010; 17:400-409.
4. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641. (Pubitemid 44232373)
5. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44:S6-S9. (Pubitemid 43053865)
6. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089.
7. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-88. (Pubitemid 351228130)
8. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848. (Pubitemid 39628231)
9. Reiberger T, Rasoul-Rockenschaub S, Rieger A, Ferenci P, Gangl A, Peck-Radosavljevic M. Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection. Eur J Clin Invest 2008; 38:421-429. (Pubitemid 351712930)
10. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450. (Pubitemid 38988593)
11. Lissen E, Clumeck N, Sola R, et al. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 2006; 20:2175-2181. (Pubitemid 44684708)
12. Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF, et al. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol 2007; 46:613-619. (Pubitemid 46402952)
13. Butt AA, Justice AC, Skanderson M, Good C, Kwoh CK. Rates and predictors of hepatitis C virus treatment in HCV-HIV- coinfected subjects. Aliment Pharmacol Ther 2006; 24:585-591. (Pubitemid 44127839)
14. Butt AA, Khan UA, Shaikh OS, et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/ HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 2009; 10:25-32.
15. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97-100. (Pubitemid 36099103)
16. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80. (Pubitemid 30038386)
17. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46:37-47. (Pubitemid 47171919)
18. Reiberger T, Aberle JH, Kundi M, et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or nonresponse in HIV-HCV coinfection. Antivir Ther 2008; 13:969-976.
19. Taylor LE. Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin Infect Dis 2005; 40 Suppl 5:S355-S361. (Pubitemid 40490225)
20. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-193. (Pubitemid 32591499)
21. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67:117-123. (Pubitemid 34722399)
22. el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123:476-482.
23. Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002; 63:194-198. (Pubitemid 34407077)
24. Van Thiel DH, Friedlander L, De Maria N, Molloy PJ, Kania RJ, Colantoni A. Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepatogastroenterology 1998; 45:328-330. (Pubitemid 28167645)
25. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21:983-991. (Pubitemid 46684329)
26. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138:513-521.
27. Zangerle R, Jöchl M, Gogl S. 15th Annual report of the Austrian HIV cohort study (AHIVCOS). HIV-Kohortenbericht 2009; 15:1-75.
28. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
29. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33:126-133.
30. Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22:270-277.
31. Payer BA, Reiberger T, Rutter K, et al. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J Clin Virol 2010; 49:131-133.
32. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008; 47:36-49. (Pubitemid 351619367)
33. Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55. (Pubitemid 41772515)